Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Proshares Trust (ZBIO) Depreciation & Amortization (CF) (2023 - 2025)

Historic Depreciation & Amortization (CF) for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to $11000.0.

  • Zenas BioPharma's Depreciation & Amortization (CF) fell 6944.44% to $11000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $79000.0, marking a year-over-year decrease of 4104.48%. This contributed to the annual value of $137000.0 for FY2024, which is 2123.89% up from last year.
  • Per Zenas BioPharma's latest filing, its Depreciation & Amortization (CF) stood at $11000.0 for Q3 2025, which was down 6944.44% from $12000.0 recorded in Q2 2025.
  • In the past 5 years, Zenas BioPharma's Depreciation & Amortization (CF) ranged from a high of $36000.0 in Q3 2024 and a low of $11000.0 during Q3 2025
  • For the 3-year period, Zenas BioPharma's Depreciation & Amortization (CF) averaged around $26625.0, with its median value being $31500.0 (2023).
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first soared by 1000.0% in 2024, then plummeted by 6944.44% in 2025.
  • Quarter analysis of 3 years shows Zenas BioPharma's Depreciation & Amortization (CF) stood at $30000.0 in 2023, then increased by 10.0% to $33000.0 in 2024, then plummeted by 66.67% to $11000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $11000.0 in Q3 2025, compared to $12000.0 in Q2 2025 and $23000.0 in Q1 2025.